Changing Faces: Agency, consultancy, and investor, February 2026

February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the lowdown.

Langland promotes creative leader. Andrew Morley was appointed executive creative director at Langland, the London-based marketing and commercial agency and Publicis Health subsidiary. A long-standing member of the Langland team, Morley has played a central part in shaping some of the agency's most celebrated creative work, earning multiple Cannes Lions in the process – including two Golds – and contributing to two Agency of the Year accolades.

Beghou appoints growth veteran to newly created president role. Beghou, a long-term consulting and technology partner to more than 200 life sciences clients, brought in Meredith Ressi as president and chief growth officer. Ressi brings more than two decades of experience driving growth at digital health and life sciences companies to the role.

PrecisionAQ strengthens data and evidence capabilities. Two significant appointments were made at PrecisionAQ, a global commercialisation partner for life sciences innovators. Yahya Anvar joined as SVP of data strategy and AI, bringing decades of experience spanning artificial intelligence, advanced analytics, and enterprise data strategy across life sciences and healthcare. Emma Hawe took up the role of SVP for evidence synthesis and decision making. Hawe currently serves as chair of the HEOR Excellence-Methodology Award for ISPOR, the Professional Society for Health Economics and Outcomes Research.

Immunology luminary moves into venture. Jeff Bluestone was named managing director of Vie Ventures, a Boston-based life sciences investment firm that operates at the intersection of venture capital and disease philanthropy. A world-renowned immunologist, Bluestone founded and led some of the field's most significant institutions: he served as the founding director of the Immune Tolerance Network and as founding CEO of the Parker Institute for Cancer Immunotherapy. Most recently, he co-founded and led Sonoma Biotherapeutics, a company developing engineered regulatory T-cell therapies.

That about does it for February agency and consultancy hires, but stay tuned for our other hires round-ups and remember, you can send your own hires to editorial@pharmaphorum.com for inclusion in this column.